News from Decision Resources, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

14 Oct, 2013, 09:00 ET Latuda Has the Greatest Commercial Potential Among New Agents Entering the Bipolar Disorder Drug Market Through 2022

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Dainippon...


10 Oct, 2013, 09:00 ET From 2012 to 2022, the Rheumatoid Arthritis Market Will Grow Moderately, Although Market Share of TNF-alpha Inhibitors Will Decrease From 73 Percent to 53 Percent

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the...


09 Oct, 2013, 10:15 ET The Ulcerative Colitis Drug Market Will Increase From $2.1 Billion in 2012 to $3.6 Billion in 2022

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the...


08 Oct, 2013, 10:30 ET For Multi-Drug-Resistant Gram-Negative Infections, Surveyed Physicians Are Likely To Use High-Priced Antibiotics With Superior Efficacy Approved Under Proposed LPAD Pathway

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a majority of...


02 Oct, 2013, 08:00 ET Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through analysis...


02 Oct, 2013, 08:00 ET Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through...


26 Sep, 2013, 09:00 ET Branded Behavioral Health Drugs May Be Constrained on Health Exchange-Based Plans

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that branded...


25 Sep, 2013, 12:00 ET In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to...


25 Sep, 2013, 08:00 ET In The Face Of Increasing Healthcare Spend And High-Cost Targeted Treatment, Market Access Barriers Continue To Rise For Targeted Oncology Drugs

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite being...


24 Sep, 2013, 12:45 ET The HONDA Patient Population- Hypertensive, Obese, Non-Compliant, Diabetic and Asthmatics- in the U.S. is a Significant Driver of Healthcare Costs

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the top 20...


23 Sep, 2013, 09:00 ET Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists' Top Unmet Need in Mild to Moderate Alzheimer's Disease

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that drugs...


10 Sep, 2013, 10:30 ET Sale of Cardiology Practices to Hospitals Challenges Marketers of Branded Therapies

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the decision by...


09 Sep, 2013, 10:00 ET Several Market Access Drivers Provide Attractive Opportunities for Multinational Companies in Saudi Arabia's Pharmaceutical Market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Saudi Arabia's...


03 Sep, 2013, 09:00 ET Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idec's Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of...


29 Aug, 2013, 09:30 ET Among the Novel Oral Anticoagulants, Bayer/Janssen's Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that...


28 Aug, 2013, 09:00 ET Differences Over Pathways Developed by Oncologists and MCOs May Create Conflict Over Prescribing Decisions in Early-Line Treatment

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that clinical...


28 Aug, 2013, 09:00 ET Novel LABA/LAMA Products Will Capture Greater Market Share than the LABA/ICS or LAMA Drug Classes by 2022

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug...


26 Aug, 2013, 10:00 ET Efficacy Advantages and Long-Term Cost Savings Will Help Optimize Reimbursement in the EU5 for Type 2 Diabetes Agents

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that as the...


22 Aug, 2013, 11:30 ET The Breast Cancer Market Is Set to Grow to More Than $15 Billion by 2022

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of...


22 Aug, 2013, 09:30 ET Roche/Chugai's Bitopertin Will Garner Nearly $1.5 Billion in Major-Market Sales in 2022 as the First Approved Treatment for Negative Symptoms in Schizophrenia

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that...